Veterinary Medicine - March 2008 - (Page Virbac3)

antiseptics, and systemic steroids, either oral or injectable. However, the long-term use of these drugs can lead to antibiotic resistance or immunosuppression. Glycotechnology offers practitioners an effective alternative without these drawbacks of traditional therapy. For more information about products with Glycotechnology, please visit www.virbacvet.com Table 1. Research findings Studies show the sugars used in glycotechnology are effective against four common dermatologic conditions: infection with Pseudomonas aeruginosa, Staphylococcus intermedius, and Malassezia pachydermatis, as well as skin inflammation. Percentage of Pseudomonas adherence1,2 3 sugars*: 46.6% L-rhamnose: D-galactose: D-mannose: Adherence reduced by > 50% 72.6% 79.2% 80.9% References 1. McEwan NA, Reme CA, Gatto H. Sugar inhibition of adherence by Pseudomonas to canine corneocytes. Vet Dermatol 2005;16:204-205. 2. McEwan NA, Reme CA, Gatto H. Monosaccharide inhibition of adherence by Pseudomonas to canine corneocytes, in Proceedings. 2nd Virbac European Symposium, Glycotechnology in Veterinary Dermatology: A New Era, 2005;17-19. 3. Ibisch C, Bourdeau P, Cadiot P, et al. Upregulation of TNF- production by INF- and LPS in cultured canine keratinocytes: application to monosaccharide effects. Vet. Res. Communications 2007;31:835-846. 4. McEwan NA, Reme CA, Gatto H, et al. Sugar inhibition of adherence by Staphylococcus intermedius to canine corneocytes. Vet Dermatol 2006;17:358. 5. McEwan NA, Kelly R, Wooley K, et al. Sugar inhibition of Malassezia pachydermatis to canine corneocytes. Vet Dermatol 2007;3:187-188. Control: 100% 0 20 40 60 80 100 Percentage of Staphylococcus adherence4 Alkylpolyglucoside: 47.7% Fructooligosaccharide: 96% Control: 100% 0 20 40 Adherence reduced by > 50% 60 80 100 Percentage of Malassezia adherence5 Alkylpolyglucoside: 58.1% 3 sugars*: 74.6% L-rhamnose: D-mannose: Adherence reduced by 42% 79.4% 90.7% Control: 100% 0 20 40 60 80 100 Exogenous sugars Glycotechnology uses three monosaccharides and one polysaccharide to inhibit pathogen adherence to the skin: • D-mannose • D-galactose • L-rhamnose • Alkylpolyglucoside. Percentage of residual TNF- secretion3 L-rhamnose: Reduced by 75% 25% Dexamethasone: 44% Control: 100% 0 *Combination of L-rhamnose, D-galactose, 20 and 40 D-mannose 60 80 100 Key points Glycotechnology uses exogenous sugars that mimic natural skin sugars to inhibit pathogen adherence to the skin. Studies have shown that glycotechnology helps reduce a variety of skin infections by 50% and inflammation by 75%. Glycotechnology-based products, unlike some other topical products, do not lead to antibiotic resistance or immunosuppresion. http://www.virbacvet.com

Table of Contents Feed for the Digital Edition of Veterinary Medicine - March 2008

Veterinary Medicine - March 2008 Contents Toxicology Brief Idea Exchange A Challenging Case An Update on Diagnosing and Treating Primary Lung Tumors CE Form Product Preview Advertiser Index Marketplace/Classifieds Mind Over Miller

Veterinary Medicine - March 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.